Anipryl Tabs 30mg [Teal]
Anipryl (selegiline hydrochloride, L-deprenyl hydrochloride) tablets are indicated for the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS) and control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH).
Zoetis
selegiline HCl (L-deprenyl HCl)
Tablets
For use in dogs only
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
DESCRIPTION: Anipryl (selegiline hydrochloride) tablets are white, convex tablets containing 2, 5, 10, 15, and 30 mg of selegiline HCl. It is commonly referred to in the clinical and pharmacological literature as L-deprenyl (the levorotatory form of deprenyl HCl).
Selegiline hydrochloride is(-)-(R)-N,α-Dimethyl-N-2-propynylphenethylamine hydrochloride.
Molecular Formula: C13H17N HCl
Molecular Weight: 223.75
PHARMACOLOGY: Selegiline is an irreversible inhibitor of monoamine oxidase (MAO).1,2 MAOs are widely distributed throughout the body and are subclassified into 2 types, A and B, which differ in their substrate specificity and tissue distribution. Selegiline is believed to be a selective inhibitor of MAO-B at recommended dosages in the dog due to its greater affinity for type B enzyme active sites compared to type A sites.1 In CNS neurons, MAO plays a role in the catabolism of catecholamines, (dopamine, and, to a lesser extent, norepinephrine and epinephrine) and serotonin.1,2 Selegiline may have pharmacologic effects unrelated to MAO-B inhibition. There is some evidence that it may increase dopaminergic activity by other mechanisms, including increasing synthesis and release of dopamine into the synapse as well as interfering with dopamine re-uptake from the synapse.2-4 Effects resulting from selegiline administration may also be mediated through its metabolites. Two of its 3 principal metabolites, L-amphetamine and L-methamphetamine, have pharmacologic actions of their own. However, the extent to which these metabolites contribute to the effects of selegiline is unknown.
Therapeutic effects of selegiline are thought to result in part from enhanced catecholaminergic nerve function and increased dopamine levels in the CNS.5,6 The pathogenesis of the development of clinical signs associated with cognitive decline is considered to be partly a result of a decrease in the level of catecholamines in the CNS and deficiencies in neurotransmission.7 There is evidence which points to hypothalamic dopamine deficiency playing a role in the pathogenesis of pituitary dependent hyperadrenocorticism in the dog.8,9
Based upon IV administration of selegiline to 4 mixed breed female dogs, the plasma elimination half-life was estimated to be 60 ± 10 minutes (mean ± SD) and the volume of distribution at steady-state (Vss) was estimated to be 9.4 ± 1.6 L/kg (mean ± SD). The relatively large Vss suggests that the selegiline is extensively distributed to body tissues. The absolute bioavailability, F, of an oral solution was less than 10%.10
INDICATIONS: Anipryl tablets are indicated for the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS) and control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH).
CONTRAINDICATIONS: Anipryl is contraindicated in patients with known hypersensitivity to this drug.
In humans, selegiline is contraindicated for use with meperidine and this contraindication is often extended to other opioids.
WARNINGS: Keep out of reach of children. Not for human use.